The Metabolic Optimizer
Advanced Obesity Drug 9604 (GH fragment 176-191)
AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) that retains the fat-metabolizing activity of GH without its growth-promoting effects. Originally developed as an anti-obesity drug, it has also shown promise for joint health, cartilage repair, and metabolic support. It received GRAS (Generally Recognized as Safe) status from the FDA in 2014 for use as a food supplement.
AOD-9604 mimics the fat-metabolizing portion of growth hormone by stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (new fat formation), without activating the IGF-1 pathway or producing growth-promoting effects.
Stimulates lipolysis (fat breakdown) in adipose tissue through a mechanism similar to growth hormone's fat-mobilizing action.
Inhibits lipogenesis (new fat cell formation), preventing the body from converting excess calories into stored fat as readily.
Does not increase IGF-1 levels, avoiding the growth-promoting effects and potential risks associated with elevated IGF-1.
Emerging evidence suggests chondroprotective properties, with potential benefits for cartilage health and osteoarthritis.
Directly stimulates fat breakdown and inhibits new fat formation through growth hormone-like pathways without IGF-1 elevation.
Unlike full GH or other GH peptides, AOD-9604 does not raise IGF-1 levels, avoiding associated risks and making it suitable for broader patient populations.
Emerging research shows potential for cartilage repair and joint health, with applications being explored for osteoarthritis treatment.
Received Generally Recognized as Safe designation from FDA in 2014, providing a higher level of safety confidence than most peptides.
AOD-9604 stimulated lipolysis and inhibited lipogenesis in human adipose tissue without affecting IGF-1 levels or producing diabetogenic effects.
Phase II clinical trial in obese subjects showed AOD-9604 produced significant body weight reduction compared to placebo over 12 weeks of treatment.
AOD-9604 demonstrated chondroprotective effects and promoted cartilage repair in osteoarthritis models, opening a new therapeutic application.
AOD-9604 has undergone clinical trials and received FDA GRAS status in 2014, indicating a strong safety profile. It does not affect blood sugar levels, does not raise IGF-1, and has minimal side effects in clinical settings.
Research Status
AOD-9604 has completed Phase II clinical trials for obesity and received FDA GRAS designation. Clinical evidence for fat metabolism is solid. Emerging research for joint health applications is promising but in earlier stages.
Regulatory Note
FDA GRAS (Generally Recognized as Safe) designation received in 2014. Not FDA-approved as a drug. Available through compounding pharmacies with physician prescription and in some supplement formulations.